The FDA has revised its emergency use authorization (EUA) for two monoclonal antibody combinations to treat mild-to-moderate COVID-19 because they are not effective against the dominant Omicron variant.
, which recently advised against use of the drugs due to reduced activity against Omicron and because real-time testing to identify rare, non-Omicron variants is not readily available.
“Because data show these treatments are highly unlikely to be active against the Omicron variant, which is circulating at a very high frequency throughout the United States, these treatments are not authorized for use in any U.S.
Indonesia Berita Terbaru, Indonesia Berita utama
Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.
FDA Curbs Use of COVID-19 Antibody Drugs Sidelined by OmicronU.S. health officials say COVID-19 antibody drugs from Regeneron and Eli Lilly should no longer be used because they are unlikely to work against the omicron variant.
Baca lebih lajut »
COVID-19 live updates: New Zealand imposes restrictions amid omicron outbreakNew Zealand Prime Minister Jacinda Ardern revealed that her own wedding will be postponed as she announced a new set of COVID-19 restrictions amid the country’s first omicron outbreak.
Baca lebih lajut »
Stealth omicron: New COVID-19 sub-variant seen in 40 countriesThe subvariant could be more contagious, scientists say.
Baca lebih lajut »
Pfizer starts clinical trial for omicron-specific Covid vaccineJUST IN: Pfizer and BioNTech announce that they have started a clinical trial testing a modified Covid-19 vaccine to protect against the omicron variant.
Baca lebih lajut »
Pfizer Begins Clinical Trial for Omicron-Specific COVID VaccinePfizer has begun a study comparing its original COVID-19 vaccine with doses specially tweaked to match the omicron variant
Baca lebih lajut »
Clinical Trials Begin For Pfizer And BioNTech’s Omicron-Specific Covid ShotI am a London-based reporter for Forbes covering breaking news. Previously, I have worked as a reporter for a specialist legal publication covering big data and as a freelance journalist and policy analyst covering science, tech and health. I have a master’s degree in Biological Natural Sciences and a master’s degree in the History and Philosophy of Science from the University of Cambridge. Follow me on Twitter theroberthart or email me at rhartforbes.com
Baca lebih lajut »